Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial
Published version of a preprint
The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Abstract
Abstract Purpose: Expression-based classifiers to predict pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) are not routinely used in the clinic. We aimed to build and validate a classifier for pCR after NACT. Patients and Methods: We performed a prospective multicenter study (EXPRESSION) including 114 patients treated with anthracycline/taxane-based NACT. Pretreatment core needle biopsies from 91 patients were used for gene expression analysis and classifier construction, followed by validation in five external cohorts (n = 619). Results: A 20-gene classifier established in the EXPRESSION cohort using a Youden index–based cut-off point predicted pCR in the validation cohorts with an accuracy, AUC, negative predictive value (NPV), positive predictive value, sensitivity, and specificity of 0.811, 0.768, 0.829, 0.587, 0.216, and 0.962, respectively. Alternatively, aiming for a high NPV by defining the cut-off point for classification based on the complete responder with the lowest predicted probability of pCR in the EXPRESSION cohort led to an NPV of 0.960 upon external validation. With this extreme-low cut-off point, a recommendation to not treat with anthracycline/taxane-based NACT would be possible for 121 of 619 unselected patients (19.5%) and 112 of 322 patients with luminal breast cancer (34.8%). The analysis of the molecular subtypes showed that the identification of patients who do not achieve a pCR by the 20-gene classifier was particularly relevant in luminal breast cancer. Conclusions: The novel 20-gene classifier reliably identifies patients who do not achieve a pCR in about one third of luminal breast cancers in both the EXPRESSION and combined validation cohorts.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Gianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
Self-citationSpring, L. M., Fell, G., Arfe, A., Sharma, C., Greenup, R., Reynolds, K. L., Smith, B. L., Alexander, B., Moy, B., Isakoff, S. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3492 · Cited by 938
Chang, J. C., Wooten, E. C., Tsimelzon, A., Hilsenbeck, S. G., Gutierrez, M. C., Elledge, R., Mohsin, S., Osborne, C. K., Chamness, G. C., Allred, D. C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14023-8 · Cited by 875
The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
Schmidt, M., Böhm, D., von Törne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kölbl, H., & Gehrmann, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5206 · Cited by 836
Self-citationHess, K. R., Anderson, K., Symmans, W. F., Valero, V., Ibrahim, N., Mejia, J. A., Booser, D., Theriault, R. L., Buzdar, A. U., Dempsey, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.6861 · Cited by 721
Hatzis, C. (2011) · JAMA · doi:10.1001/jama.2011.593 · Cited by 699
Burstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Colleoni, M., Denkert, C., Piccart-Gebhart, M., Regan, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz235 · Cited by 667
Self-citationA stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer
Farmer, P., Bonnefoi, H., Anderle, P., Cameron, D., Wirapati, P., Becette, V., André, S., Piccart, M., Campone, M., Brain, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.1908 · Cited by 623
Cited by
Li, B., Li, F., Liu, Z., Xu, F., Ye, G., Li, W., Zhang, Y., Zhu, T., Shao, L., Chen, C., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.10.004 · Cited by 48
“In addition, some models have been proposed for predicting the pCR to NAC from different prospects, including clinic-pathological variables [6,7], genomic signatures [8], and even radiomic features from pretreatment [9] and mid-treatment [10] magnetic resonance imaging (MRI).”
MethodChen, J., Li, H., Qian, X., Lin, L., Pan, Y., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948601 · Cited by 43
“The optimal threshold values should therefore be calibrated or adjusted for some purpose (18) in different cohorts.”
BackgroundResultImmunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice
Schmidt, M., & Heimes, A.-S. (2021) · Cancers · doi:10.3390/cancers13194883 · Cited by 30
“Recently, in the neoadjuvant EXPRESSION trial, we demonstrated that genes with significantly higher expression in pathologically complete responders are primarily related to the immune response, including immunoglobulins [33].”
BackgroundSelf-citationLiverani, C., Vita, A. D., Spadazzi, C., Miserocchi, G., Cocchi, C., Bongiovanni, A., Lucia, A. D., Manna, F. L., Fabbri, F., Tebaldi, M., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13037 · Cited by 25
Using biological constraints to improve prediction in precision oncology
Omar, M., Dinalankara, W., Mulder, L., Coady, T., Zanettini, C., Imada, E. L., Younes, L., Geman, D., & Marchionni, L. (2023) · iScience · doi:10.1016/j.isci.2023.106108 · Cited by 12
“, 2011), GSE25065, GSE140494 (Edlund et al., 2021), GSE103668 (Birkbak et al.”
Metadata
- Authors
- Edlund, K., Madjar, K., Lebrecht, A., Aktas, B., Pilch, H., Hoffmann, G., Hofmann, M., Kolberg, H.-C., Boehm, D., Battista, M., Seehase, M., Stewen, K., Gebhard, S., Cadenas, C., Marchan, R., Brenner, W., Hasenburg, A., Koelbl, H., Solbach, C., Gehrmann, M., Tanner, B., Weber, K. E., Loibl, S., Sachinidis, A., Rahnenführer, J., Schmidt, M., & Hengstler, J. G.
- Affiliations
- TU Dortmund University (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- University Hospital Leipzig (DE)
- University Hospital Cologne (DE)
- St. Josefs Hospital (DE)
- Marienhospital Stuttgart (DE)
- Marienhospital Bottrop (DE)
- 9Center of Minimal Invasive Surgery, Senology and Oncology, mic.ma.mainz, Mainz, Germany.
- University of Vienna (AT)
- University Hospital Frankfurt (DE)
- Bayer (Germany) (DE)
- 13Practice for Gynecological Oncology, Hoen Neuendorf, Germany.
- German Breast Group (DE)
- University of Cologne (DE)
- Corresponding author
- Hengstler, Jan G.
- ORCID
- Edlund, Karolina
- Madjar, Katrin
- Aktas, Bahriye
- Kolberg, Hans-Christian
- Battista, Marco
- Gebhard, Susanne
- Cadenas, Cristina
- Marchan, Rosemarie
- Brenner, Walburgis
- Hasenburg, Annette
- Solbach, Christine
- Gehrmann, Mathias
- Weber, Karsten E.
- Loibl, Sibylle
- Sachinidis, Agapios
- Rahnenführer, Jörg
- Schmidt, Marcus
- Hengstler, Jan G.
- Venue
- Clinical Cancer Research
- Published
- 2021-02-04
- Volume
- 27
- Issue
- 8
- Pages
- 2148-2158
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W3129134217
- Cited by
- 24
- References
- 50
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 4 · 2021: 3
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Funders
- Federal Ministry of Education and Research (01GR0816)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- early breast cancer, neoadjuvant chemotherapy, pathological complete response, gene expression classifier, luminal breast cancer, molecular subtypes, treatment de-escalation, external validation
- MeSH terms
- Clinical Decision-Making, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Mastectomy, Middle Aged, Neoplasm Staging, Predictive Value of Tests, Prognosis, Prospective Studies, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Treatment Outcome, Chemotherapy, Adjuvant, Patient Selection, Neoadjuvant Therapy, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2662
- The paper
- Edlund, K., Madjar, K., Lebrecht, A., Aktas, B., Pilch, H., Hoffmann, G., Hofmann, M., Kolberg, H.-C., Boehm, D., Battista, M., Seehase, M., Stewen, K., Gebhard, S., Cadenas, C., Marchan, R., Brenner, W., Hasenburg, A., Koelbl, H., Solbach, C., . . . Hengstler, J. G. (2021). Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2662
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.